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ABSTRACT
b-catenin mediates Wnt/wingless signaling and
transcriptional activation by lymphocyte enhancer
binding factor 1/T cell factor (LEF1/TCF) proteins
with the assistance of multiple coregulators, includ-
ing positive cofactors like p300/CBP and negative
cofactors like HDACs. We previously demonstrated
that a developmentally essential protein, Flightless-I
(Fli-I), serves as a coactivator for nuclear receptor-
mediated transcription. To further understand the
action mechanism of Fli-I, we investigated the
functional roles of Fli-I and Fli-I leucine rich repeat
associated protein 1 (FLAP1) in transcriptional
activation by b-catenin and LEF1/TCF. b-catenin-
dependent transcription was activated by exoge-
nous FLAP1 but inhibited by Fli-I. Reduction of
endogenous FLAP1 levels compromised transcrip-
tional activation by LEF1/TCF, b-catenin and the
p160 coactivator GRIP1. FLAP1 interacted directly
with b-catenin, GRIP1 and p300 and enhanced their
activity. Furthermore, FLAP1 was strongly synergis-
tic with p300 in supporting transcriptional activation
by b-catenin and LEF1/TCF, but Fli-I disrupted
the synergy of FLAP1 with p300 and b-catenin.
Thus the opposing effects of Fli-I and FLAP1 may be
a key regulatory mechanism for b-catenin and
LEF1/TCF-mediated transcription and thus for Wnt
signaling, and some mutations of Fli-I may result in
developmental defects, such as the flightless
phenotype of Drosophila, by causing dysregulation
of the Wnt/b-catenin pathway.
INTRODUCTION
b-catenin is an essential factor in various developmental and
pathological processes of animals from Drosophila to humans
(1,2). b-catenin has important roles in regulating cell–cell
contacts and actin cytoskeleton conﬁguration (3). b-catenin
is also involved in the Wnt/wingless signaling pathway and
acts as a coactivator for the lymphocyte enhancer binding
factor 1/T cell factor (LEF1/TCF) family of transcriptional
activator proteins (1). Binding of Wnt ligand to a Frizzled
receptor leads to the activation of Disheveled protein and
the inhibition of kinase activity of the glycogen synthase
kinase-3B/Axin/adenomatous polyposis coli complex. This
prevents phosphorylation of b-catenin and thus results in
stabilization of b-catenin in the cytoplasm. The accumulated
b-catenin protein translocates into the nucleus, where it binds
to and enhances transcriptional activation by LEF1/TCF (4).
The b-catenin-LEF1/TCF complex regulates the expression
of the c-Myc and cyclin D1 genes among others. b-catenin
and LEF1/TCF dependent gene expression is regulated by
the interplay of various coregulators. Positive transcription
regulators for b-catenin and LEF1/TCF include p300/CBP
(5–7), BRG1 (8), the p160 coactivator GRIP1 (9,10) and
CARM1 (11). Negative regulators of b-catenin and LEF1/
TCF include HDACs, CtBP, Groucho and Chibby (4,12–16).
Interestingly, the b-catenin mediated pathway has crosstalk
with nuclear receptor (NR) dependent pathways. b-catenin
interacts directly with androgen receptor (AR) and acts as a
coactivator for AR-dependent transcription (10,17,18).
Some common coactivators, including b-catenin and p300,
mediate transcriptional activation by LEF1/TCF and NRs
(5–7,9–11). These coactivators enhance transcription activa-
tion by remodeling chromatin and by direct interaction with
other components of the transcription machinery. Many
coactivators form complexes that synergistically enhance
transcriptional activation. For example, the three p160
coactivators (SRC1, GRIP1/TIF2, pCIP/ACTR/AIB1/RAC3/
TRAM1) interact with other coactivators like the protein
acetyltransferase p300 and coactivator associated arginine
methyltransferase 1 (CARM1) to regulate histone acetylation
and methylation. The C-terminal activation domain (AD) 2 of
GRIP1 binds to CARM1 and the adjacent domain AD1 binds
to p300/CBP (19). In addition, the N-terminal AD3 domain of
GRIP1 interacts with Fli-I (Flightless-I) and other coactiva-
tors (18,20,21). Many of these components cooperate syner-
gistically as coactivators for various DNA-binding
transcription factors. For example, CARM1 and p300 syner-
gistically enhance the activity of NR, b-catenin, p53, NFkB
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and Fli-I show synergy in the activation of NR-dependent
transcription (20)
Previously, we identiﬁed Fli-I as a CARM1 binding protein
and as a coactivator for NR-dependent transcription (20). Fli-I
was originally characterized as a developmentally essential
protein in Drosophila (25). Severe mutations or homozygous
knock-out of the gene encoding Fli-I lead to impaired cellular-
ization and gastrulation of Drosophila embryos and early
embryonic death in mice (26). Even mild mutations of Fli-I
in Drosophila cause defects in the development of ﬂight mus-
cles and a loss-of-ﬂight phenotype. The human Fli-I gene is
located in a region of chromosome 17p which is associated
with Smith-Magenis syndrome, a genetic disease causing
developmental and behavioral abnormalities (27). In spite of
the developmental signiﬁcance of Fli-I, its biochemical roles
remain to be further elucidated. Fli-I has a highly conserved
protein structure among Drosophila, mouse and human (25),
with a leucine rich repeat (LRR) motif at the N-terminus
and a gelsolin-like domain in the C-terminal region. The
C-terminal region of human Fli-I has 31% identity and 52%
similarity to human gelsolin, which is a member of an
actin-binding protein family. The gelsolin-like domain of
Fli-I interacts with actin and the actin-like protein BAF53
(Brg1 associated factor 53), which are both components of
the Swi/Snf complex (20,28). In cultured cells Fli-I can be
in the nucleus or associated with actin in the cytoskeleton,
depending on the serum levels and growth conditions,
suggesting multiple roles for Fli-I in transcription and
cytoskeleton regulation (29). As with the LRR-motifs of
other proteins, the LRR domain of Fli-I consists of 16 tandem
LRRs. Proteins with LRR domains have diverse cellular local-
ization and functions such as transcription and signal transduc-
tion (30). LRR domains often function in protein–protein
interactions. To understand the roles of Fli-I LRR, two inde-
pendent groups identiﬁed interacting proteins by yeast two-
hybrid screening (31,32). These include mouse Fli-I LRR
associating protein 1 (FLAP1) and human LRR Fli-I inter-
acting proteins 1 and 2 (LRRFIP1 and 2). A related protein,
the human immunodeﬁciency virus TAR RNA interacting
protein (TRIP), was isolated by another group of investigators
(33). Interestingly, all of these proteins, FLAP1, LRRFIP1 and
2 and TRIP have similar sequences and predicted structure
rich in alpha-helices and coiled-coils. However, the
biochemical functions of these proteins remain obscure.
In this study, we investigated the functional roles of Fli-I
and FLAP1 in regulating transcriptional activation by
b-catenin and LEF1/TCF. FLAP1 is a key activator, cooper-
ating synergistically with p300 to mediate transcriptional
activation by b-catenin and LEF1/TCF. This synergy of
FLAP1 and p300 was negatively regulated by Fli-I. This
study suggests that the interplay of Fli-I and FLAP1 may
be one of the important regulation mechanisms of the
b-catenin dependent, Wnt signaling pathway.
MATERIALS AND METHODS
Plasmids
A FLAP1 expression vector, pCMV-FLAP1 was obtained
from Dr Helen L. Yin (University of Texas Southwestern
Medical Center) (32). The other constructs were described
in previous publications as follows: coactivator expression
vectors: pSG5-HA.GRIP1, pSG5-HA.CARM1, pCMV-p300,
pSG5.HA (24); Fli-I expression vectors: pcDNA-Fli-I,
pSG5-ﬂag.LRR and pSG65-ﬂag.Gelsolin (20); GST-protein
expression vectors: pGEX4T-KIX, pGEX4T-GBD (34);
pGEX4T-GRIP1N, pGEX4T-GRIP1M, pGEX4T-GRIP1C,
pGEX4T-ER (24); pGEX-b-catenin, pGEX-LEF1, TOP-
ﬂash, pGL3OT-luc, pSG5-HA.b-catenin, pSG5-HA.LEF1,
pM-b-catenin (9,11); pM-GRIP1N, pM-GRIP1M and
pM-GRIP1C (19).
Transfection
293T cells were transfected with plasmids by using F1
Targefect reagent (Targeting Systems) according to the
manufacturer’s protocol as described previously (20,24).
Luciferase activity was measured after 40 h. Results shown
are the mean and deviations from mean of two transfected
cultures. Luciferase assay data shown are representative of
at least three independent experiments.
GST-pulldown assay
The procedure for GST-pulldown assays was described
previously (20,34) and used GST fusion proteins produced
in Escherichia coli BL21 cells. The transformed E.coli cells
were induced by IPTG and lysed by sonication. GST-fused
proteins were collected by incubation with glutathione
Sepharose beads.
Co-immunoprecipitation and immunoblot
The co-immunoprecipitation assay was described previously
(20,24). One microgram of anti-ﬂag antibody (Sigma) and
protein A/G agarose were incubated with cell extracts. The
immunoprecipitated fractions were washed and analyzed by
immunoblot analysis with anti-HA antibody (Roche).
siRNA
siRNA assays were described previously (20,34). siRNAs
for FLAP1 (designed from the human LRRFIP1 seq-
uence in GenBank accession no. NM_004735) are as
follows. siFLAP1A: (sense) AGCCGGGAGAUCGACUGU-
UdTdT, (anti-sense) AACAGUCGAUCUCCCGGCUdTdT;
siFLAP1B: (sense) GAAACACAUCGGCUUCUGAdTdT,
(anti-sense) UCAGAAGCCGAUGUGUUUCdTdT.
Sequences of siRNAs for Fli-I, AIB1 and CARM1 were
described previously (20). Transfections were performed by
using oligofectamin or lipofectamine 2000 (invitrogen).
MCF-7 and 293T cells were used for this assay. FLAP1
antibody (BD Transduction laboratories) was used in
immunoblots for detecting endogenous FLAP1 in MCF7
cells.
RESULTS
FLAP1 and Fli-I regulate transcription mediated by
b-catenin and LEF1
LEF1/TCF-mediated transcription was examined by transfec-
tion of the pGL3OT-Luc or TOPﬂash-luc reporter plasmid
(regulated by binding sites for LEF1/TCF) into mammalian
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reporter in 293T cells (Figure 1A, bar 2) and transfection
of increasing amounts of FLAP1 expression plasmid led to
a dramatic activation of LEF1/TCF-dependent transcription
(bars 3–5). In contrast, over-expression of Fli-I did not
affect transcription activation by b-catenin and LEF1/TCF
(bars 9–11). GRIP1 also cooperated with b-catenin to
enhance LEF1/TCF-dependent transcription (bars 6–8) as
previously shown (9,10).
To test the effects of FLAP1 and Fli-I on b-catenin activity
in a one hybrid assay, a plasmid encoding GAL4 DBD fused
to b-catenin was transfected along with the GK1-luc reporter
plasmid, which is controlled by binding sites for GAL4 DBD.
GAL4 DBD fused to b-catenin enhanced expression of the
GK1-luc reporter gene (Figure 1B, bar 2) and co-expression
of FLAP1 further enhanced b-catenin-mediated transcrip-
tional activation (bar 3). Surprisingly, over-expressed Fli-I
strongly inhibited b-catenin activity (bar 4). However, the
LRR and gelsolin fragments of Fli-I caused little if any
inhibition of b-catenin-mediated transcription (bars 5 and
6), even though these Fli-I fragments were expressed at
higher levels than full length Fli-I (20). This result suggests
that both LRR and gelsolin domains are required for the
inhibitory effect of Fli-I on b-catenin activity. Thus, FLAP1
enhanced LEF1/TCF-mediated transcription (Figure 1A)
and b-catenin dependent transcription (Figure 1B), while
full-length Fli-I acted as a negative regulator of b-catenin-
dependent transcription (Figure 1B).
siRNAs for FLAP1 inhibit LEF1/TCF mediated
transcription
Two siRNAs for FLAP1 (designed according to the sequence
of the human ortholog LRRFIP1) efﬁciently reduced the
level of endogenous FLAP1/LRRFIP1 in MCF-7 cells
(Figure 2A, bottom panel). However, siRNAs for Fli-I,
AIB1 and CARM1 did not affect the endogenous protein
level of FLAP1. The siRNAs for Fli-I, AIB1 and CARM1
were previously demonstrated to cause reduced levels of
the corresponding endogenous proteins (20). The roles of
endogenous FLAP1 and Fli-I in transcription mediated
by b-catenin and LEF1/TCF were ﬁrst tested in MCF-7
cells, which have elevated levels of Wnt (35,36). The
Figure 1. FLAP1 and Fli-I regulate b-catenin and LEF1/TCF-mediated
transcription. (A) Reporter plasmid pGL3OT-luc (0.2 mg) was transfected
into 293T cells in 12-well dishes along with pSG5-bCAT (0.2 mg) and
pCMV-FLAP1, pSG5.HA-GRIP1 or pcDNA-Fli-I (0.2–0.6 mg) as indicated.
(B) Reporter plasmid GK1-Luc (0.2 mg) was transfected into 293T cells
with 0.2 mg of each of the following plasmids, as indicated: pM-b-catenin,
pCMV-FLAP1, pcDNA-Fli-I, pSG5-Fli-LRR, pSG5-Fli-Gelsolin.
Figure 2. Inhibition of LEF1/TCF-mediated and GRIP1-mediated transcrip-
tion by siRNAs for FLAP1. (A) TOPflash reporter plasmid (0.5 mg) was
transfected into MCF-7 cells in 12-well dishes along with 50 pmol of siRNA
for FLAP1, Fli-I, AIB1 or CARM1. Luciferase activity was measured at 40 h
(top panel) and part of each cell extract was analyzed by immunoblot with 1
mg of anti-FLAP1 antibody to monitor the endogenous level of FLAP1
protein (bottom panel). (B) GK1 reporter plasmid (0.2 mg) was transfected
into 293T cells along with pM-GRIP1N, pM-GRIP1M or pM-GRIP1C
(0.2 mg) and 50 pmol of siRNAs for FLAP1.
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basal activity in MCF-7 cells, but reduction of endogenous
FLAP1 by siRNAs reduced TOPﬂash expression
(Figure 2A, upper panel, bars 1–3). siRNA for AIB1 also sup-
pressed TOPﬂash expression, but siRNAs for CARM1 and
Fli-I had little effect (bars 4–6). Similar results were obtained
in 293T cells or when a different LEF1/TCF-dependent
reporter plasmid, pGL3OT-luc, was used (data not shown).
These results suggest that endogenous FLAP1 is an essential
coactivator for LEF1/TCF mediated transcription.
Interaction of FLAP1 with b-catenin and other
coactivators
Endogenous and exogenous FLAP1 has coactivator activity
for b-catenin mediated, LEF1/TCF dependent-transcription
(Figures 1 and 2). To deﬁne molecular interactions that
may contribute to these activities of FLAP1, GST-pulldown
assays were performed (Figure 3A). FLAP1 synthesized in
vitro bound to GST-fused b-catenin, but not to GST-LEF1
and GST controls. FLAP1 also interacted with N- and C-
terminus, but not with the middle region, of GRIP1. In con-
trast, the N-terminal LRR fragment of Fli-I bound to the
GRIP1 N-terminal region but not to any of the other GST
fusion proteins tested, as shown previously (20). Roughly
equivalent levels of all the GST fusion proteins were loaded
onto the glutathione-Sepharose beads, except that somewhat
lower levels of GST-GRIP1M were used (Supplementary
Figure 6A).
Previously, Moon and colleagues showed that the C-
terminal region of b-catenin interacts with the KIX domain
of CBP, a homolog of p300 (7). FLAP1 also interacted
with p300 through the KIX domain but did not interact
with the GRIP1 binding domain (GBD) of p300 or with
GST (Supplementary Figure 6B).
In co-immunoprecipitation assays, FLAP1 associated
strongly with the C-terminal fragment of GRIP1 and weakly
with the N-terminus of GRIP1 and with b-catenin (Figure 3B,
upper panel, lanes 3, 5 and 6). The relatively weak interac-
tions observed may indicate that these proteins associate tran-
siently rather than stably. However, FLAP1 did not interact
with LEF1 (lane 7). The HA-tagged GRIP1 fragments, b-
catenin and LEF1 were expressed well in 293T cells
(Figure 3B, lower panel). Thus, the co-immunoprecipitation
results (Figure 3B) were consistent with the GST-pulldown
data (Figure 3A), indicating that FLAP1 binds to GRIP1,
b-catenin and p300 in vitro and/or in mammalian cells.
However, FLAP1 does not bind to LEF1, indicating that
FLAP1 functions as a secondary coactivator for LEF1/TCF,
i.e. the physical and functional interaction of FLAP1 with
LEF1/TCF is mediated by one of the other coactivators.
Figure 3. Interaction of FLAP1 with b-catenin and other coactivators. (A)
GST-pulldown assay: in vitro translated FLAP1 protein or Fli-I LRR
fragment was incubated with purified GST fusion proteins (1 mg) bound to
glutathione-Sepharose beads. Bound protein fractions were analyzed by
immunoblot with anti-Flag antibodies. (B) Co-immunoprecipitation assay:
2 mg of expression vectors pCMV-flag-FLAP1, pSG5.HA.GRIP1N,
pSG5.HA.GRIP1M, pSG5.HA.GRIP1C, pSG5.HA.b-catenin and pSG5.HA.-
LEF1 were transfected into 293T cells as indicated. After 40 h, transfected
cells were collected and lysed with RIPA buffer. Two percent of cell extracts
were loaded into a separate gel for loading control and analyzed by
immunoblot with anti-HA antibody (lower panel). One microgram of anti-
Flag antibody was added to the remaining extract with protein A/G agarose
beads. Anti-HA antibody (0.2 mg of antibody per 1 ml of blocking buffer) was
used to detect the co-precipitated proteins by immunoblot (upper panel).
(C) Mammalian one hybrid assay: 0.2 mg of GK1-Luc, pM-GRIP1N,
pM-GRIP1M and pM-GRIP1C were transfected along with 0.2 mgo f
pCMV-FLAP1 and pCMV-p300 vectors as indicated.
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domains of GRIP1
p300/CBP binds to and activates the middle domain of
GRIP1, which contains AD1 (21). Since FLAP1 binds to
both N- and C-termini of GRIP1, we tested the effects of
FLAP1 and p300 on the three activation domains of GRIP1
fused to GAL4 DBD. The autonomous transcription activa-
tion activities of GRIP1N and GRIP1C (Figure 3C, bars 2)
were further enhanced by the expression of FLAP1
(bars 3), but not by p300 (bars 4). In contrast, the autonomous
activity of GRIP1M was enhanced by p300, but not by
FLAP1. This shows that FLAP1 activates the activation
domains in the N- and C-termini of GRIP1, while p300
activates AD1, located in the middle-domain of GRIP1. In
support of these conclusions, siRNAs for FLAP1 speciﬁcally
inhibited transcriptional activation by GRIP1N and GRIP1C,
but not GRIP1M, fused to GAL4 DBD (Figure 2B, bars 3 and
4). Endogenous FLAP1 therefore has a selective role in medi-
ating transcriptional activation by GRIP1N and C, but not by
GRIP1M. Thus, FLAP1 binds to various coactivators includ-
ing b-catenin, GRIP1 and p300 and may contribute to the
transcription-enhancing activity of b-catenin by direct contact
with one or more of these coactivators.
Synergistic enhancement by FLAP1 and p300 of
transcriptional activation by b-catenin and LEF1/TCF
or by androgen receptor
FLAP1 and p300 independently enhanced the transcriptional
activity of b-catenin tethered to GAL4 DBD (Figure 4A,
bars 3 and 4). However, when both FLAP1 and p300 were
co-expressed, the b-catenin-dependent transcription was syn-
ergistically activated (bar 5). In addition, FLAP1 and p300
independently enhanced LEF1/TCF-dependent transcription
in the presence of b-catenin (Figure 4B, bars 4–6). However,
the co-expression of FLAP1, p300 and b-catenin caused
synergistic enhancement of LEF1/TCF mediated transcription
(bar 8). The coactivator synergy of FLAP1 and p300 was
not observed without the expression of b-catenin (bar 7),
consistent with our ﬁnding that FLAP1 does not bind to
LEF1/TCF (Figure 3A). The synergy of FLAP1 and p300
was also observed in TOPﬂash reporter assay system
(Figure 4C, bar 5), but not with FOPﬂash reporter (which
has mutant TCF/LEF binding sites) (bar 10). This shows
that the synergy of FLAP1 and p300 is dependent upon the
binding of LEF1/TCF to DNA.
The synergy of FLAP1 and p300 was also investigated in
an AR-mediated transcription system. The mouse mammary
tumor virus (MMTV)-luc reporter plasmid (which has bind-
ing sites for AR) was transfected into 293T cells along with
an AR expression vector and the cells were treated with dihy-
drotestosterone (DHT). FLAP1 or p300 individually had little
effect on AR-mediated transcription (Figure 4D, bars 3 and
4). However, when FLAP1 and p300 were expressed
together, AR-mediated transcription was synergistically acti-
vated (bars 10 and 11) and this synergy was dependent on the
co-expression of either b-catenin or GRIP1 (bar 7). Thus, the
combination of FLAP1 and p300 without b-catenin or GRIP1
was not very effective in the activation of AR-mediated trans-
cription. Thus, FLAP1 cooperates synergistically with p300
Figure 4. Synergy of FLAP1 and p300 for enhancement of transcriptional
activation by b-catenin, LEF1/TCF and AR. (A) Mammalian one hybrid
assay was performed as follows: GK1-Luc, pCMV-FLAP1 and pCMV-p300
(0.2 mg of each) were transfected into 293T cells as indicated. Luciferase
activity was measured at 40 h. (B) LEF1/TCF-dependent transient
transfection assay was performed with pGL3OT-luc reporter plasmid as
follows: pGL3OT-luc, pCMV-FLAP1, pCMV-p300, pSG5-bCAT, pSG5.HA-
GRIP1 and pcDNA-Fli-I (0.2 mg of each as indicated) were transfected into
293T cells. (C) LEF1/TCF-dependent transient transfection assay was
performed with TOP/FOP reporter plasmids as follows: TOPflash-luc,
FOPflash-luc, pCMV-FLAP1, pCMV-p300 and pSG5-bCAT (0.2 mg of each
as indicated) were transfected into 293T cells. (D) AR-dependent transient
transfection assays were performed as follows: MMTV-luc, pCMV-FLAP1,
pCMV-p300, pSG5-b-catenin and pSG5.HA-GRIP1 (0.2 mg of each as
indicated) and 10 ng of AR expression vector were transfected into 293T
cells. 100 mM of DHT was added after transfection.
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by LEF1/TCF or AR, by binding to the primary coactivator
b-catenin or GRIP1. In spite of its dependence on GRIP1
or b-catenin for its coactivator function with AR and ER
(37), we found that FLAP1 did bind to at least some
NRs. FLAP1 bound to estrogen receptor (ER) in a ligand-
independent manner (Supplementary Figure 6C). However,
over-expression of FLAP1 alone was not able to enhance
transcriptional activation by either of the two activation
domains of ER, AF1 or AF2, which were fused to GAL4
DBD (Supplementary Figure 6D). In contrast, the activities
of both ERAF1 and ERAF2 were enhanced by the
co-expression of p300.
Fli-I inhibits the synergy of FLAP1 and p300
Fli-I was previously characterized as a coactivator for NRs
and Fli-I functions synergistically with GRIP1 and CARM1
as a coactivator for NRs (20). Since Fli-I also binds to
FLAP1 (32) and inhibits b-catenin mediated transcription
(Figure 1B), we investigated the effect of Fli-I on the synergy
of FLAP1 and p300. As previously shown (Figure 4), FLAP1
and p300 synergistically enhanced transcriptional activation
by b-catenin fused to GAL4 DBD (bar 8, Figure 5A).
However, the coactivator synergy of FLAP1 and p300 was
inhibited severely by co-transfection of increasing amounts
of Fli-I expression vectors (lanes 9–13). The LRR and
gelsolin-like fragments of Fli-I were less effective inhibitors
of b-catenin mediated transcription (bars 5–8, Figure 5B),
although they are expressed at higher levels than full length
Fli-I (20). This suggests that functions of both the LRR and
gelsolin-like domains are required for the inhibitory activity
of Fli-I. Thus, although Fli-I cooperates synergistically in
GRIP1 coactivator complexes with NRs, Fli-I negatively
regulates the activity of b-catenin coactivator complexes.
As an initial investigation of the mechanism of this negative
regulation, we tested whether Fli-I fragments might inhibit
binding of FLAP1 to p300. However, the LRR and Gelsolin-
like fragments of Fli-I bound weakly or not at all to the p300
KIX domain (Supplementary Figure 6E and data not shown).
We further tested whether the LRR and Gelsolin-like frag-
ments of Fli-I could interfere with the binding of FLAP1 to
the p300 KIX domain fused to GST. However, when 5-fold
excess levels of in vitro translated LRR and Gelsolin-like
fragments were mixed and incubated with in vitro translated
FLAP1 and bead-bound GST-KIX, there was no reduction in
binding of FLAP1 to the beads (Supplementary Figure 6F),
suggesting that Fli-I does not interfere with the binding of
FLAP1 to p300. Thus, the mechanism for the inhibitory effect
of Fli-I on the coactivator function of b-catenin, FLAP1 and
p300 remains to be determined.
DISCUSSION
FLAP1 activates b-catenin/LEF1/TCF-mediated
transcription.
FLAP1, its apparent human ortholog LRRFIP1 and another
homologous human protein LRRFIP2 were originally identi-
ﬁed as proteins that bind to the LRR domain of Fli-I (31,32).
Another protein, TRIP, was identiﬁed as a TAR RNA binding
protein and also has signiﬁcant homology with FLAP1 (33).
However, the functional roles of FLAP1 and the other
Fli-LRR interacting molecules are not well characterized.
The current study shows that FLAP1 is required for efﬁcient
transcriptional activation by b-catenin and LEF1/TCF
(Figures 1 and 2). FLAP1 acts as a coactivator by binding
to the activation domains of other coactivators like GRIP1
and b-catenin and enhancing their activity (Figure 3).
Recently, LRRFIP2 was shown to be a strong activator
for b-catenin dependent transcription (38) and a dominant
negative form of LRRFIP2 suppressed Wnt signaling in
Xenopus. This is consistent with our data showing an impor-
tant role for FLAP1 in b-catenin dependent transcription.
LRRFIP2 interacts with Dvl (disheveled) and activates
the cytoplasmic part of the Wnt/b-catenin pathway (38).
However, our study shows that mouse FLAP1 (and therefore
Figure 5. Fli-I inhibits the synergy of FLAP1 and p300. (A) and (B).
Mammalian one hybrid assay: GK1-Luc, pM-b-catenin, pCMV-FLAP1,
pCMV-p300, pSG5-LRR, pSG5-Gelsolin (0.1 mg of each as indicated), were
transfected into 293T cells. Variable amounts of Fli-I expression vectors were
used: A, bar 5: 0.1 mg; Bars 9–13: 0.2, 0.1, 0.05, 0.025, 0.01 mg. B, bar 6:
0.1 mg. (C) Model: Interplay of Fli-I and FLAP1 for regulating b-catenin
mediated gene expression. b-catenin is translocated into the nucleus and
interacts with LEF1/TCF to activate transcription. bcatenin recruits other
coregulators to modulate LEF1/TCF-mediated transcription. b-catenin
interacts with FLAP1, p300 and GRIP1 to activate transcription synergisti-
cally. However, elevated levels of Fli-I protein shut down FLAP1-dependent
b-catenin/LEF1/TCF mediated transcription activation.
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nuclear proteins like GRIP1 and p300 and cooperates with
these coactivators to enhance transcriptional activation by
b-catenin and its associated DNA-binding transcription
factors. Thus, it is possible that FLAP1 may activate the
Wnt/b-catenin pathway at both the cytoplasmic and nuclear
levels. Since FLAP1 and LRRFIP2 are 58% identical in
amino acid sequence (by comparison of GenBank accession
numbers AAC40072 and AAD41257), FLAP1 may also
interact with Dvl and activate the cytoplasmic pathway of
b-catenin. On the other hand, it is possible that FLAP1 may
have a unique mechanism, which is different from that of
LRRFIP2. For example, FLAP1 may primarily act inside
the nucleus and LRRFIP2 in the cytoplasm, such that they
contribute in a complementary way to regulation of Wnt/
b-catenin signaling. Thus, FLAP1, LRRFIP1, LRRFIP2 and
TRIP may comprise a family of proteins, which regulate
Wnt/b-catenin signaling through a variety of mechanisms.
This study also suggests that FLAP1 cooperates with p300
for the activation of b-catenin dependent, LEF1/TCF
mediated and AR-mediated transcription (Figure 5). This is
reminiscent of the synergy of CARM1 and p300 or the
synergy of CARM1 and Fli-I (11,20,24). The synergy of all
these secondary coactivators, including FLAP1, requires the
co-expression of a primary coactivator, such as GRIP1 or
b-catenin. GRIP1 or b-catenin may act as a bridge factor
for stabilizing the coactivator complex, although FLAP1
interacts directly with p300 in vitro (Supplementary Figure
6). Alternatively, by associating directly with the DNA
bound transcription factor (LEF1/TCF or NR), GRIP1 and
b-catenin may provide a platform for recruiting FLAP1 and
p300 to the promoter. GRIP1 and b-catenin may have over-
lapping or complementary roles in promoting the synergistic
action of FLAP1 and p300. FLAP1 shows a unique pattern of
coactivator binding and transcription activation, which is
distinguished from p300 and other coactivators. FLAP1,
p300 and CARM1 bind to different ADs of GRIP1 and
presumably transmit output signals to different downstream
targets in the transcription machinery, thus accounting for
their synergistic cooperation. The fact that FLAP1 and p300
together interact with all three ADs of GRIP1 may explain
why this combination of coactivators yields such a strong
synergy with GRIP1 and b-catenin. Overall, our results sug-
gest that FLAP1 may be an essential partner molecule which
cooperates with p300 to mediate the Wnt signaling pathway
(Figure 5C).
Implications of inhibitory roles of Fli-I in b-catenin
mediated transcription and Wnt/Wingless signaling
Fli-I was originally identiﬁed as an essential protein for the
development of Drosophila and mouse. Since Fli-I, like
b-catenin, is associated with the actin cytoskeleton in the
cytoplasm and shuttles between nucleus and cytoplasm
(29), the possible involvement of Fli-I in the b-catenin/
LEF1/TCF pathway was previously suggested (20). Here,
we demonstrated that, in addition to its previously iden-
tiﬁed coactivator function with NRs, Fli-I has important
roles in the regulation of the b-catenin/LEF1/TCF mediated
pathway. Fli-I suppresses b-catenin/LEF1/TCF mediated
transcription, whereas FLAP1 has the opposite effect
(Figure 5C). Our initial studies on the negative regulation
of b-catenin-p300-FLAP1 activity by Fli-I found that Fli-I
does not bind well to p300 KIX domain and does not appear
to inhibit FLAP1-p300 binding (Supplementary Figure 6E
and F). Fli-I may exert its negative inﬂuence by squelching
the activity of FLAP1 and other essential factors that bind
to Fli-I. It is also possible that Fli-I may recruit negative regu-
lators, such as HDACs, CtBP, Groucho and Chibby, to the
b-catenin/LEF1/TCF transcription complex. Both the LRR
and gelsolin-like domains of Fli-I are required for the
negative regulation of b-catenin function (Figures 1 and 5).
However, while the LRR domain binds to FLAP1, the
inhibitory mechanisms of the gelsolin-like domain are less
clear. Some of the interactions of the gelsolin domain, i.e.
with BAF53 (a component of the Swi/Snf complex),
CARM1, actin and other proteins (20,29), may provide
clues to the mechanism by which Fli-I inhibits b-catenin
mediated transcription. Since Fli-I acts positively on NR-
mediated transcription (20) and negatively on b-catenin/
LEF1/TCF mediated function (Figure 5), Fli-I may help to
determine the balance between NR and b-catenin/LEF1/
TCF activity. Increased nuclear levels of Fli-I would presum-
ably favor NR-mediated transcription, while lowered nuclear
levels of Fli-I or increased FLAP1 levels would probably
result in the release of FLAP1 and support the activation of
b-catenin/LEF1/TCF-mediated transcription through the
synergy of FLAP1 and p300. Thus, Fli-I and FLAP1 have
antagonistic roles in the regulation of b-catenin/LEF1/TCF
mediated transcription and may play key roles in the regula-
tion of the Wnt/Wingless-signaling pathway. In addition,
interactions of Fli-I and FLAP1 with other proteins may
also be crucial for the regulation of these pathways. It follows
that mutations in Fli-I may result in dysregulation of the
b-catenin pathway and Wnt/Wingless-signaling and thus
may account for the previously reported developmental abnor-
malities of Fli-I mutants (1,2,25). Furthermore, the opposing
roles of FLAP1 and Fli-I may have signiﬁcance for the pro-
cess of carcinogenesis. Since b-catenin over-expression is
important in many cancers, FLAP1 and Fli-I may play roles
as oncogene and tumor suppressor, respectively.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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